Additionally, we posit that investigational drugs targeting HIF-1α catabolism, ROS inhibition, GPR91 stimulation, PHD activity promotion and tumor-promoting inflammation should be developed to improve clinical treatment. This evidence concerns the gene SUCNR1 and neoplasm.